98 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
4 Jun 24
Regulation FD Disclosure
9:30am
% in the uproleselan arm (n=80) and 46.2% in the placebo arm (n=78). Safety Adverse events were consistent with the known safety profile for backbone
8-K
EX-99.2
GLYC
GlycoMimetics Inc
4 Jun 24
Regulation FD Disclosure
9:30am
safety or efficacy data, unexpected side effects observed during preclinical studies or in clinical trials, whether results of early clinical trials … ) MRD- Status (N=144) Depth of Response and Transplant Transplantation Status Yes (N=200) No (N=188) AEs & Serious TEAEs Safety and Tolerability
8-K
EX-99.2
GLYC
GlycoMimetics Inc
6 May 24
Results of Operations and Financial Condition
4:01pm
between our expectations and actual results include unexpected safety or efficacy data, unexpected side effectsobserved during preclinical studies … ,R.T. Hoeg, A.S. Rosenberg, L. Molnar, A. Linh Dang-Chu, S.L. steward, and J.M. Tuscano, 2022 PublicationNumber: 2764 Encouraging safety and evidence
8-K
EX-99.1
l3dcr 7oayuz7ifbxd
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
PRE 14A
s37k 0t4g6amh3
22 Mar 24
Preliminary proxy
5:00pm
8-K
EX-99.1
b923s4gi
1 Mar 24
Regulation FD Disclosure
9:16am
8-K
EX-99.1
u4otx1yxavf5gl
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
8-K
EX-99.1
npbt1slk7qn
2 Aug 23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8:35am